# Novel Gene Therapy, Techniques, and Devices to Prevent Ventricular Tachycardia

> **NIH NIH R44** · RITHIM BIOLOGICS, INC. · 2024 · $317,285

## Abstract

ABSTRACT
 In the United States, several hundred thousand people experience cardiac arrest each year, with the vast
majority dying from this condition. Approximately two-thirds of cardiac arrest victims have previously suffered a
myocardial infarction (MI), and death results from maladaptive responses to infarct healing. The healed infarct
scar creates a substrate that supports malignant ventricular arrhythmias, and death results from ventricular
tachycardia (VT) originating in the border zone around the infarct scar. We recently reported that the
potassium channel beta subunits KCNE3 and KCNE4 are upregulated only in VT circuits, and that these
proteins cause a pattern of repolarization heterogeneity that supports reentrant VT. We previously developed
an epicardial gene painting method for transmural atrial gene transfer, and we have preliminary data showing
that use of epicardial gene painting with adeno-associated virus vectors allows complete transmural ventricular
gene transfer. In a successful STTR grant, we developed a prototype catheter that would allow epicardial gene
painting without opening the chest. In this fast track SBIR proposal, we exploit these findings to develop a cure
for post-infarct VT. We hypothesize that the VT circuit-specific repolarization effects create an environment
conducive for reentry VT, and that normalizing repolarization will prevent VT. To test our hypothesis, we
propose phase 1 experiments that finalize development of the gene painting catheter, verify ventricular-
targeted transgene expression with the gene painting catheter, and evaluate biodistribution and toxicity in sinus
rhythm animals. Phase 2 is a fully powered efficacy and safety study in our clinically relevant pig model of
post-infarct VT. Successful completion of these aims will create a preclinical data package required to support
future clinical testing of VT gene therapy.

## Key facts

- **NIH application ID:** 10822751
- **Project number:** 1R44HL172541-01
- **Recipient organization:** RITHIM BIOLOGICS, INC.
- **Principal Investigator:** Ronald Lee Anderson
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $317,285
- **Award type:** 1
- **Project period:** 2024-08-15 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10822751

## Citation

> US National Institutes of Health, RePORTER application 10822751, Novel Gene Therapy, Techniques, and Devices to Prevent Ventricular Tachycardia (1R44HL172541-01). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10822751. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*